Best Life Sciences Companies in Basel Landschaft, Switzerland
The 35 best Life Sciences companies in Basel Landschaft, Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Santhera.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Basel Landschaft
| # | Company | Last round | Disclosed funding | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AlphaMol Developer of drug molecules to treat multiple disease conditions | — | — | — | Shuguang Yuan Co-Founder | — | — | — | — |
| 2 | Argo Therapeutics Developer of therapeutics for neurological disorders | — | — | — | Alexander Breidenbach Co-Founder | — | — | — | — |
| 3 | BioInitials Manufacturer of non-invasive medical devices to monitor the oral cavity | — | — | — | Saso Jezernik Co-Founder | — | — | 12 patents Smart toothbrushes integrating oral health analytics and respiratory risk sensing devices. | — |
| 4 | CIS Pharma Developer of pharmaceuticals, biomaterials, and medical devices for oncology and ophthalmology | — | — | — | Christoph Schafer CEO | — | — | 64 patents Polymeric drug delivery carriers and hyaluronic‑acid ophthalmic formulations for therapeutics | — |
| 5 | CorasMedical Developer of a implantable blood pump for axial flow ventricular assist | — | — | 2 | — | — | — | — | — |
| 6 | HUBERLAB Online supplier of medical and laboratory equipment | — | — | 15 | — | Cart FunctionalitySAP Commerce CloudJava+21 | Top 5M | — | — |
| 7 | InCephalo Developer of therapeutics for neurological disorders | — | — | 9 | Carlo Bertozzi Co-Founder & CEO | WordPressMySQLPHP+16 | Top 50M | — | — |
| 8 | Infors HT Offering bioreactors, incubation shakers and bioprocess platform software | — | — | 94 | — | Kentico CMSWindows ServerReact+11 | Top 5M | 77 patents Patents concentrated in transport & manufacturing processes | — |
Top 12 Life Sciences companies in Basel Landschaft
#1
Public · Liestal, Basel Landschaft · founded 2004 · 73 employees$159.1Mraised▾
Developer of drugs for treating mitochondrial and neuromuscular diseases. The company has developed Vamorolone a dissociative steroid with a novel mode of action for the treatment of Duchenne muscular dystrophy.
- Feb 2023Post IPO—
- Sep 2021Grant (prize money)$1.2M
- Sep 2021Post IPO$48.3M
- Apr 2021Post IPO$64.1M
#2
Series A · Allschwil, Basel Landschaft · founded 2019 · 9 employees$26.2Mraised▾
Synendos Therapeutics is a developer of endocannabinoid modulators for the treatment of CNS disorders. It has developed pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric disorders. The company is developing small molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders caused by cannabinoid deficiency.
- Apr 2021Series A$4.4M
- Nov 2020Series A$21.9M
- Jan 2020Grant (prize money)$55.1K
- Aug 2019Grant (prize money)$55.4K
#3
Series A · Muttenz, Basel Landschaft · founded 2016 · 27 employees$7.2Mraised▾
Developer of quantum-based scanning probe microscopic equipment. It uses quantum mechanics to control the state of a single electron using which it measures the electric and magnetic fields. The company uses diamond-based nanosensors to provide applications in superconductivity, microwave imaging, magnetic nanomemories, and antiferromagnetic RAM.
- May 2021Series A$4.4M
- Nov 2019Seed$2.6M
- Jun 2018Seed$131.7K
- Jun 2018Grant (prize money)$109.4K
#4
Public · Allschwil, Basel Landschaft · founded 1996 · 119 employees$39.7Mraised▾
Polyphor is developing macrocycle drugs for infections, breast cancer, cystic fibrosis, and others. It has developed proprietary technologies PEMfinder and MacroFinder. Its drug pipeline includes antibiotic (Murepavadin, an amino-acid cyclic peptide, targets lipopolysaccharide transport protein D on the bacterial cell membrane) for Pseudomonas infections (Phase 2), OMPTA platform targeting Gram-negative resistant pathogens, POL6326, a CXCR4 antagonist for metastatic breast cancer, Myelodysplastic syndromes, POL6014, a protease inhibitor for Cystic fibrosis, and Alpha-1 Antitrypsin Deficiency.
#5
Series A · Reinach, Basel Landschaft · founded 2015 · 17 employees$33Mraised▾
Developer of synthetic carbohydrate vaccines for drug-resistant infectious diseases. The company has proprietary technology based on the research on parts of the sugar coating of the bacteria that are actually necessary to trigger an immune response. It is advancing vaccine candidates using homogeneous, synthetically produced carbohydrate antigens and novel carrier molecules for the prevention of infectious diseases.
- Aug 2019Grant (prize money)$1.4M
- Jun 2015Series A$33M
#6
Seed · Allschwil, Basel Landschaft · founded 2017 · 16 employees$12.8Mraised▾
Versameb is developing therapies focusing on local delivery of therapeutic proteins. They have developed a proprietary technology platform which enables optimized local delivery of therapeutic proteins which helps in increased therapeutic potency. Their lead candidate is in the preclinical stage, planning to enter clinical trials by 2020. It has applications in neuromuscular conditions and other acute & chronic conditions.
- Jul 2020Seed$6.4M
- Oct 2019Seed$6.4M
- Dec 2018Seed—
#7
Acquired · Reinach, Basel Landschaft · founded 1997 · 45 employees$90.4Mraised▾
Arpida (SIX: ARPN) is a biopharmaceutical company headquartered in Reinach, near Basel, Switzerland with operations in Switzerland and the USA. It focuses on novel drugs that seek to overcome the growing problem of microbial resistance. Arpida's leading product candidate is intravenous iclaprim, an antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
#8
Acquired · Allschwil, Basel Landschaft · founded 1997 · 4008 employees$46Mraised▾
Actelion specializes in small molecule therapeutics for orphan diseases. Actelion scientists were among the first to work in the field of endothelian receptor antagonists. Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases: Tracleer (bosentan), a dual endothelin receptor antagonist which was the first oral treatment approved for pulmonary arterial hypertension; Zavesca (miglustat), currently the only approved oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Ventavis (iloprost), indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms; Veletri (epoprostenol for injection), approved for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequ
#9
Acquired · Liestal, Basel Landschaft · founded 1997 · 71 employees$607.1Kraised▾
Provider of nano-microscopes for industrial and academic research. It specializes in atomic force microscopes (AFM) and scanning tunneling microscopes (STM). These are used for metrological surface inspections and for the visualization of structures on the nanometer scale. The range of products offered also includes Flex-FPM, a microfluidic tool for nanomanipulation and single-cell biology, Cytomass Monitor for measuring and monitoring the mass of a single cell in physiological conditions, LensAFM to extend the resolution of an upright microscope or 3D profilometer, and others.
- Dec 2017Grant (prize money)$214.9K
- Jul 2017Grant (prize money)$200.5K
- Jan 2017Grant (prize money)$191.7K
#10
Funding Raised · Liestal, Basel Landschaft · founded 2015$119.6Kraised▾
Nexilis develops proprietary device products for fixation of implants. They have developed an Immediate Stabilisation System (implantable polymeric tube). The extracellular matrix (ECM) coating allows coating of implants with a native extracellular matrix.
- Jun 2018Grant (prize money)$58.2K
- Mar 2018Grant (prize money)$61.3K
#11
Late Stage · Allschwil, Basel Landschaft · founded 1996 · 28 employees—raised▾
Developer of antibiotic therapeutics for the treatment of cancer and rare diseases. The product pipeline of the company includes ColiFin for cystic fibrosis, EBX-002, a combination of amikacin (AMK) and a potentiator molecule for NTM infections, and Balixafortide, a potent and highly selective blocker of CXCR4 for advanced breast cancer, and other oncology indications.
#12
Seed · Muttenz, Basel Landschaft · founded 2014 · 15 employees—raised▾
Workflow automation device for laboratory use. The company has developed a robotic automated sample preparation device for HPLC applications. The device gets integrated with software solutions to provide overall data, sample preparation details, and more.
- Apr 2021Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Switzerland
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 469 Switzerland-affiliated papers.
- ETH Zurich52
- University of Zurich40
- University of Lausanne34
- Agroscope30
- University of Basel30
- Gene2→9
- Chromatin1→8
- Antibody3→7
- Epitope1→5
- Immune system1→4
- Population2→4
- Antimicrobial1→5
- Context (archaeology)1→4
- Agriculture2→4
Where biotechnology is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.